Similar rates of remission and sustained remission were found for people with ANCA-associated vasculitis (AAV) given induction treatment with…
Articles by Patricia Inacio, PhD
Fasenra (benralizumab) provides meaningful benefits for people with eosinophilic granulomatosis with polyangiitis (EGPA), including those testing positive for self-reactive…
People with ANCA-associated vasculitis (AAV) are at a higher risk of developing certain types of cancer, particularly bladder, blood, kidney,…
Adding Tavneos (avacopan) to standard treatment is as safe and effective in older people with ANCA-associated vasculitis (AAV)…
A higher risk of death among AAV patients with interstitial lung disease (ILD) is significantly associated with older age, episodes…
Long-term treatment with Nucala (mepolizumab) reduces disease activity and helps to prevent progressive organ damage in people with eosinophilic granulomatosis…
Plasma exchange added to standard immunosuppressive treatments helps improve early kidney function in people with ANCA-associated vasculitis (AAV) who…
High blood levels of the syndecan-1 protein, known to promote the survival of antibody-producing B cells, may help identify…
Using data from the largest ANCA-associated vasculitis (AAV) patient database compiled to date, researchers identified five new subgroups that…
Treatment with the asthma medication montelukast may trigger eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated…